In last trading session, Perspective Therapeutics Inc (AMEX:CATX) saw 0.6 million shares changing hands with its beta currently measuring 1.22. Company’s recent per share price level of $2.76 trading at -$0.08 or -2.82% at ring of the bell on the day assigns it a market valuation of $186.54M. That closing price of CATX’s stock is at a discount of -590.22% from its 52-week high price of $19.05 and is indicating a premium of 2.17% from its 52-week low price of $2.70.
For Perspective Therapeutics Inc (CATX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.20. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.25 in the current quarter.
Perspective Therapeutics Inc (AMEX:CATX) trade information
Upright in the red during last session for losing -2.82%, in the last five days CATX remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $2.76 price level, adding 14.02% to its value on the day. Perspective Therapeutics Inc’s shares saw a change of -13.48% in year-to-date performance and have moved -11.25% in past 5-day. Perspective Therapeutics Inc (AMEX:CATX) showed a performance of -23.33% in past 30-days.
Wall Street analysts have assigned a consensus price target of 21 to the stock, which implies a rise of 86.86% to its current value. Analysts have been projecting 20 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would drop -624.64% in reaching the projected high whereas dropping to the targeted low would mean a loss of -624.64% for stock’s current value.
Perspective Therapeutics Inc (CATX) estimates and forecasts
This year revenue growth is estimated to fall -2.81% from the last financial year’s standing.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 297.76k for the same. And 4 analysts are in estimates of company making revenue of 151.33k in the next quarter. Company posted -4.9M and 325k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -7.69% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 49.34% while estimates for its earnings growth in next 5 years are of 4.82%.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Advisor Biotechnology Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.69 shares of worth $4.67 million or 2.50% of the total outstanding shares. The later fund manager was in possession of 1.64 shares on Dec 31, 2024 , making its stake of worth around $4.53 million in the company or a holder of 2.43% of company’s stock.
